ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
CONSOLIDATED FINANCIAL STATEMENTS
NOTES 23-24
86/111
23 LIST OF SUBSIDIARIES - CONTINUED
Share of voting rights
and ownership
Lundbeck USA Holding LLC, USA, including
- Lundbeck LLC, USA, including
- Lundbeck NA Ltd., USA
Purpose
Other
%
100
Sales and distribution
100
- Chelsea Therapeutics International, Ltd., USA, including
Other
100
24 SUBSEQUENT EVENTS
In January 2022, Lundbeck announced that the European Commission has granted marketing
authorization for VyeptiⓇ in the European Union (EU) for the prophylactic treatment of migraine in adults
who have at least four migraine days per month. The approval follows the positive opinion on 11 November
2021 from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use
(CHMP). The marketing authorization is valid in all EU Member States, Iceland, Norway, and Liechtenstein.
Other
100
- Lundbeck Pharmaceuticals LLC, USA
Other
100
- Lundbeck Research USA, Inc., USA
- Lundbeck La Jolla Research Center, Inc., USA, including
- Abide Therapeutics (UK) Limited, UK
- Lundbeck Seattle BioPharmaceuticals, Inc., USA, including
- Alder Biopharmaceuticals Pty., Ltd., Australia
Other
100
The approval will result in an increase in the fair value of the contingent consideration payable of
approximately DKK 300 million, which will be expensed as financial items in 2022.
Research and development
100
Other
100
Research and development
100
- Alder Biopharmaceuticals Limited, Ireland
- Alderbio Holdings LLC ("ANEV"), USA
Other
Other
100
100
Other
100
Sales and distribution
100
Lundbeck de Venezuela, C.A., Venezuela
1) Lundbeck UK LLP is owned by Lundbeck Group Ltd. (Holding), Lundbeck Limited and Lifehealth Limited, all of which have H. Lundbeck A/S
as their direct or ultimate parent company.View entire presentation